Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
|---|---|---|---|---|---|---|
| Xarelto | Rivaroxaban | Deep-vein thrombosis without symptomatic pulmonary embolism | List with clinical criteria and/or conditions | Complete | ||
| Rituxan | Rituximab | Granulomatosis with polyangiitis and microscopic polyangiitis | List with clinical criteria and/or conditions | Complete | ||
| Halaven | Eribulin Mesylate | Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Byetta | Exenatide | Diabetes mellitus, type 2 | Do not list | Complete | ||
| Resotran | Prucalopride | Constipation, chronic | Do not list | Complete | ||
| Botox | OnabotulinumtoxinA | Neurogenic detrusor overactivity | List with clinical criteria and/or conditions | Complete | ||
| Actemra | Tocilizumab | Arthritis, juvenile idiopathic | List with clinical criteria and/or conditions | Complete | ||
| Saphris | Asenapine | Schizophrenia | Do not list | Complete | ||
| Effient | Prasugrel | Acute coronary syndrome | Do not list | Complete | ||
| Eliquis | Apixaban | Venous thromboembolic events, prevention | List with clinical criteria and/or conditions | Complete |
Last Updated : May 14, 2024